Recent Posts
- NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
 - Nordic Group B.V. Through its Subsidiary Nordic Pharma, Inc. (U.S.), Announces LACRIFILL® Canalicular Gel Inclusion in New Dry Eye Workshop (DEWS) III Management and Therapy Report From The Tear Film and Ocular Surface Society (TFOS) in American Journal of Ophthalmology
 - Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces launch of authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
 - Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Presenting Patient Data and Patient Experience Study for LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
 - Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Details of LACRIFILL® Canalicular Gel Poster Presentation At SECO 2025
 
Archives
- October 2025
 - August 2025
 - April 2025
 - March 2025
 - October 2024
 - May 2024
 - April 2024
 - March 2024
 - February 2024
 - January 2024
 - December 2023
 - June 2023
 - July 2022
 - June 2022
 - February 2022
 - December 2021
 - November 2021
 - October 2021
 - August 2021
 - March 2021
 - December 2020
 - August 2020
 - June 2019
 - January 2019
 - July 2018
 - June 2017
 - March 2017
 - April 2016
 - March 2016
 - January 2016
 - December 2015
 - June 2015
 
					
Recent Comments